BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

New Zealand

AIRS Medical Partners with ParagonCare to Boost SwiftMR™ Sales in Australia and New Zealand

AIRS Medical Inc., a leading provider of AI-powered healthcare solutions, has announced a strategic partnership agreement with ParagonCare Limited&nbs...

February 19, 2024 | News

Molecule AI Spearheads Pharmaceutical Transformation with AI-Driven Drug Discovery Innovations

Molecule AI, on a mission to accelerate drug discovery through the innovative use of artificial intelligence, is making significant...

January 20, 2024 | News

Biocon Biologics Successfully Integrates Acquired Biosimilars Business Across 120 Countries

Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully conc...

December 19, 2023 | News

MGI Australia Introduces Innovative CEC with DCS Lab Products for Advanced DNA, Cell, and Spatial-omics Technology

MGI Australia, a subsidiary of MGI Tech Co. Ltd. (MGI), a global leader in life science technology, is delighted to announce a substantial expans...

December 15, 2023 | News

Specialised Therapeutics Secures Exclusive License for Novel Ovarian Cancer Treatment from CanariaBio

First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progress...

October 13, 2023 | News

EQT's Acquisition: VetPartners, Key Animal Health Provider in Australia and New Zealand

EQT to acquire VetPartners, the leading provider of veterinary and animal health services across a network of 267 general practice clinics and specialty ...

October 12, 2023 | News

Specialised Therapeutics acquires commercialisation rights to new oral MND therapy

ST to partner with Dutch biotech company Treeway BV First CNS therapy in ST therapeutic portfolio The therapy is known as TW001 and is a un...

August 28, 2023 | News

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

August 08, 2023 | News

Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval

The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...

August 02, 2023 | News

Antengene's XPOVIO® Approved in Hong Kong for Relapsed Multiple Myeloma

XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...

July 17, 2023 | News

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

87% of respondents deemed mRNA a key modality for the future More than 60% of vaccine makers surveyed plan revamp or new facilities for mRNA m...

June 01, 2023 | News

Sun Pharma and Philogen Sign Exclusive Agreement for NIDLEGY™ Commercialization in Europe, Australia, and New Zealand

Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...

May 31, 2023 | News

Leading New Zealand Cancer Research Gets a Data Privacy Boost with Amaroq Therapeutics and GeneCrypt Partnership

Amaroq Therapeutics, a world-leading company based in New Zealand focused on developing a new class of therapeutics that targets long non-coding ...

May 26, 2023 | News

Formus Labs Receives FDA Clearance for AI-Powered Orthopedic Surgery Planning Technology.

Formus Labs today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for Formus Hip as th...

May 04, 2023 | News

Stay Connected